Effect of γ-L-glutamyl-L-DOPA on phosphate excretion

Shamim Sadiq, Theresa J. Berndt, Karl A Nath, Franklyn G. Knox

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

γ-L-glutamyl-L-DOPA (gludopa) is a dopamine prodrug that is relatively specific for the kidney. Because dopamine is phosphaturic, the present study compared the phosphaturic effects of the infusion of equimolar doses of gludopa (n = 8), L-DOPA (n = 8), and γ-L-glutamyl-L-tyrosine (glutyrosine, n = 6). Glutyrosine was used as a control to evaluate the effect of the glutamyl portion of gludopa on phosphate excretion. Sprague-Dawley rats (350 to 400 g) were anesthetized with 5-sec-butyl-ethyl-2-thyobarbituric acid (Inactin; 100 mg/kg, IP) and underwent thyroparathyroidectomy. Clearances were taken during the infusion of normal saline vehicle, followed by the infusion of gludopa, L-DOPA, or glutyrosine, all infused at the rate of 10 nmol/kg bolus and 0.8 nmol/kg/min (IV). To determine the contribution of glutamyl derivative to phosphate excretion, gludopa or L-DOPA was infused in the presence of SCH23390, a DA-1 receptor antagonist. Gludopa infusion significantly increased dopamine excretion (from 1.9 ± 0.2 ng/min to 17.0 ± 3.9 ng/min, Δ15.0 ± 3.9 ng/min, P < .008) and fractional excretion of phosphate (from 2.6% ± 0.6% to 34.8% ± 1.8%, Δ32.0% ± 1.6%, P < .001). L-DOPA infusion significantly increased dopamine excretion (from 1.4 ± 0.4 ng/min to 9.7 ± 1.6 ng/min, Δ8.3 ± 1.5 ng/min, P < .001) and fractional excretion of phosphate (from 1.7% ± 0.6% to 8.2% ± 2.0%, Δ6.4% ± 1.5%, P < .004). Glutyrosine infusion significantly increased fractional excretion of phosphate (from 2.8% ± 0.8% to 17.5% ± 5.2%, Δ14.6% ± 4.8%, P < .03) without changing dopamine excretion (Δ0.5 ± 0.2 ng/min). Infusion of gludopa in the presence of SCH23390 increased fractional excretion of phosphate (from 5.7% ± 2.5% to 12.6% ± 3.5%, Δ6.8% ± 2.3%, n = 6, P < .03), whereas SCH23390 completely blocked the phosphaturic effect of L-DOPA. We conclude that γ-L-glutamyl-L-DOPA is more phosphaturic than L-DOPA in the rat because of the combined effects of dopamine and the glutamyl moiety.

Original languageEnglish (US)
Pages (from-to)52-56
Number of pages5
JournalJournal of Laboratory and Clinical Medicine
Volume135
Issue number1
StatePublished - Jan 2000

Fingerprint

Dopamine
Phosphates
Rats
Prodrugs
Sprague Dawley Rats
Tyrosine
Derivatives
Kidney
Acids
gamma-glutamyltyrosine
SCH 23390

ASJC Scopus subject areas

  • Medicine(all)
  • Pathology and Forensic Medicine

Cite this

Effect of γ-L-glutamyl-L-DOPA on phosphate excretion. / Sadiq, Shamim; Berndt, Theresa J.; Nath, Karl A; Knox, Franklyn G.

In: Journal of Laboratory and Clinical Medicine, Vol. 135, No. 1, 01.2000, p. 52-56.

Research output: Contribution to journalArticle

Sadiq, S, Berndt, TJ, Nath, KA & Knox, FG 2000, 'Effect of γ-L-glutamyl-L-DOPA on phosphate excretion', Journal of Laboratory and Clinical Medicine, vol. 135, no. 1, pp. 52-56.
Sadiq, Shamim ; Berndt, Theresa J. ; Nath, Karl A ; Knox, Franklyn G. / Effect of γ-L-glutamyl-L-DOPA on phosphate excretion. In: Journal of Laboratory and Clinical Medicine. 2000 ; Vol. 135, No. 1. pp. 52-56.
@article{1f495935356142d9a552d25942eef3e0,
title = "Effect of γ-L-glutamyl-L-DOPA on phosphate excretion",
abstract = "γ-L-glutamyl-L-DOPA (gludopa) is a dopamine prodrug that is relatively specific for the kidney. Because dopamine is phosphaturic, the present study compared the phosphaturic effects of the infusion of equimolar doses of gludopa (n = 8), L-DOPA (n = 8), and γ-L-glutamyl-L-tyrosine (glutyrosine, n = 6). Glutyrosine was used as a control to evaluate the effect of the glutamyl portion of gludopa on phosphate excretion. Sprague-Dawley rats (350 to 400 g) were anesthetized with 5-sec-butyl-ethyl-2-thyobarbituric acid (Inactin; 100 mg/kg, IP) and underwent thyroparathyroidectomy. Clearances were taken during the infusion of normal saline vehicle, followed by the infusion of gludopa, L-DOPA, or glutyrosine, all infused at the rate of 10 nmol/kg bolus and 0.8 nmol/kg/min (IV). To determine the contribution of glutamyl derivative to phosphate excretion, gludopa or L-DOPA was infused in the presence of SCH23390, a DA-1 receptor antagonist. Gludopa infusion significantly increased dopamine excretion (from 1.9 ± 0.2 ng/min to 17.0 ± 3.9 ng/min, Δ15.0 ± 3.9 ng/min, P < .008) and fractional excretion of phosphate (from 2.6{\%} ± 0.6{\%} to 34.8{\%} ± 1.8{\%}, Δ32.0{\%} ± 1.6{\%}, P < .001). L-DOPA infusion significantly increased dopamine excretion (from 1.4 ± 0.4 ng/min to 9.7 ± 1.6 ng/min, Δ8.3 ± 1.5 ng/min, P < .001) and fractional excretion of phosphate (from 1.7{\%} ± 0.6{\%} to 8.2{\%} ± 2.0{\%}, Δ6.4{\%} ± 1.5{\%}, P < .004). Glutyrosine infusion significantly increased fractional excretion of phosphate (from 2.8{\%} ± 0.8{\%} to 17.5{\%} ± 5.2{\%}, Δ14.6{\%} ± 4.8{\%}, P < .03) without changing dopamine excretion (Δ0.5 ± 0.2 ng/min). Infusion of gludopa in the presence of SCH23390 increased fractional excretion of phosphate (from 5.7{\%} ± 2.5{\%} to 12.6{\%} ± 3.5{\%}, Δ6.8{\%} ± 2.3{\%}, n = 6, P < .03), whereas SCH23390 completely blocked the phosphaturic effect of L-DOPA. We conclude that γ-L-glutamyl-L-DOPA is more phosphaturic than L-DOPA in the rat because of the combined effects of dopamine and the glutamyl moiety.",
author = "Shamim Sadiq and Berndt, {Theresa J.} and Nath, {Karl A} and Knox, {Franklyn G.}",
year = "2000",
month = "1",
language = "English (US)",
volume = "135",
pages = "52--56",
journal = "Translational Research",
issn = "1931-5244",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Effect of γ-L-glutamyl-L-DOPA on phosphate excretion

AU - Sadiq, Shamim

AU - Berndt, Theresa J.

AU - Nath, Karl A

AU - Knox, Franklyn G.

PY - 2000/1

Y1 - 2000/1

N2 - γ-L-glutamyl-L-DOPA (gludopa) is a dopamine prodrug that is relatively specific for the kidney. Because dopamine is phosphaturic, the present study compared the phosphaturic effects of the infusion of equimolar doses of gludopa (n = 8), L-DOPA (n = 8), and γ-L-glutamyl-L-tyrosine (glutyrosine, n = 6). Glutyrosine was used as a control to evaluate the effect of the glutamyl portion of gludopa on phosphate excretion. Sprague-Dawley rats (350 to 400 g) were anesthetized with 5-sec-butyl-ethyl-2-thyobarbituric acid (Inactin; 100 mg/kg, IP) and underwent thyroparathyroidectomy. Clearances were taken during the infusion of normal saline vehicle, followed by the infusion of gludopa, L-DOPA, or glutyrosine, all infused at the rate of 10 nmol/kg bolus and 0.8 nmol/kg/min (IV). To determine the contribution of glutamyl derivative to phosphate excretion, gludopa or L-DOPA was infused in the presence of SCH23390, a DA-1 receptor antagonist. Gludopa infusion significantly increased dopamine excretion (from 1.9 ± 0.2 ng/min to 17.0 ± 3.9 ng/min, Δ15.0 ± 3.9 ng/min, P < .008) and fractional excretion of phosphate (from 2.6% ± 0.6% to 34.8% ± 1.8%, Δ32.0% ± 1.6%, P < .001). L-DOPA infusion significantly increased dopamine excretion (from 1.4 ± 0.4 ng/min to 9.7 ± 1.6 ng/min, Δ8.3 ± 1.5 ng/min, P < .001) and fractional excretion of phosphate (from 1.7% ± 0.6% to 8.2% ± 2.0%, Δ6.4% ± 1.5%, P < .004). Glutyrosine infusion significantly increased fractional excretion of phosphate (from 2.8% ± 0.8% to 17.5% ± 5.2%, Δ14.6% ± 4.8%, P < .03) without changing dopamine excretion (Δ0.5 ± 0.2 ng/min). Infusion of gludopa in the presence of SCH23390 increased fractional excretion of phosphate (from 5.7% ± 2.5% to 12.6% ± 3.5%, Δ6.8% ± 2.3%, n = 6, P < .03), whereas SCH23390 completely blocked the phosphaturic effect of L-DOPA. We conclude that γ-L-glutamyl-L-DOPA is more phosphaturic than L-DOPA in the rat because of the combined effects of dopamine and the glutamyl moiety.

AB - γ-L-glutamyl-L-DOPA (gludopa) is a dopamine prodrug that is relatively specific for the kidney. Because dopamine is phosphaturic, the present study compared the phosphaturic effects of the infusion of equimolar doses of gludopa (n = 8), L-DOPA (n = 8), and γ-L-glutamyl-L-tyrosine (glutyrosine, n = 6). Glutyrosine was used as a control to evaluate the effect of the glutamyl portion of gludopa on phosphate excretion. Sprague-Dawley rats (350 to 400 g) were anesthetized with 5-sec-butyl-ethyl-2-thyobarbituric acid (Inactin; 100 mg/kg, IP) and underwent thyroparathyroidectomy. Clearances were taken during the infusion of normal saline vehicle, followed by the infusion of gludopa, L-DOPA, or glutyrosine, all infused at the rate of 10 nmol/kg bolus and 0.8 nmol/kg/min (IV). To determine the contribution of glutamyl derivative to phosphate excretion, gludopa or L-DOPA was infused in the presence of SCH23390, a DA-1 receptor antagonist. Gludopa infusion significantly increased dopamine excretion (from 1.9 ± 0.2 ng/min to 17.0 ± 3.9 ng/min, Δ15.0 ± 3.9 ng/min, P < .008) and fractional excretion of phosphate (from 2.6% ± 0.6% to 34.8% ± 1.8%, Δ32.0% ± 1.6%, P < .001). L-DOPA infusion significantly increased dopamine excretion (from 1.4 ± 0.4 ng/min to 9.7 ± 1.6 ng/min, Δ8.3 ± 1.5 ng/min, P < .001) and fractional excretion of phosphate (from 1.7% ± 0.6% to 8.2% ± 2.0%, Δ6.4% ± 1.5%, P < .004). Glutyrosine infusion significantly increased fractional excretion of phosphate (from 2.8% ± 0.8% to 17.5% ± 5.2%, Δ14.6% ± 4.8%, P < .03) without changing dopamine excretion (Δ0.5 ± 0.2 ng/min). Infusion of gludopa in the presence of SCH23390 increased fractional excretion of phosphate (from 5.7% ± 2.5% to 12.6% ± 3.5%, Δ6.8% ± 2.3%, n = 6, P < .03), whereas SCH23390 completely blocked the phosphaturic effect of L-DOPA. We conclude that γ-L-glutamyl-L-DOPA is more phosphaturic than L-DOPA in the rat because of the combined effects of dopamine and the glutamyl moiety.

UR - http://www.scopus.com/inward/record.url?scp=0033987904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033987904&partnerID=8YFLogxK

M3 - Article

C2 - 10638694

AN - SCOPUS:0033987904

VL - 135

SP - 52

EP - 56

JO - Translational Research

JF - Translational Research

SN - 1931-5244

IS - 1

ER -